These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 39322664)
1. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Bai Z; Feng B; McClory SE; de Oliveira BC; Diorio C; Gregoire C; Tao B; Yang L; Zhao Z; Peng L; Sferruzza G; Zhou L; Zhou X; Kerr J; Baysoy A; Su G; Yang M; Camara PG; Chen S; Tang L; June CH; Melenhorst JJ; Grupp SA; Fan R Nature; 2024 Oct; 634(8034):702-711. PubMed ID: 39322664 [TBL] [Abstract][Full Text] [Related]
2. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631 [TBL] [Abstract][Full Text] [Related]
3. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088 [TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
5. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014 [TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis. Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355 [TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients. Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185 [TBL] [Abstract][Full Text] [Related]
10. CD4 Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717 [TBL] [Abstract][Full Text] [Related]
11. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Bai Z; Woodhouse S; Zhao Z; Arya R; Govek K; Kim D; Lundh S; Baysoy A; Sun H; Deng Y; Xiao Y; Barrett DM; Myers RM; Grupp SA; June CH; Fan R; Camara PG; Melenhorst JJ Sci Adv; 2022 Jun; 8(23):eabj2820. PubMed ID: 35675405 [TBL] [Abstract][Full Text] [Related]
13. Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia. Hashem Boroojerdi M; Rahbarizadeh F; Safarzadeh Kozani P; Kamali E; Safarzadeh Kozani P Med Oncol; 2020 Oct; 37(11):100. PubMed ID: 33047234 [TBL] [Abstract][Full Text] [Related]
14. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. Weng J; Lai P; Qin L; Lai Y; Jiang Z; Luo C; Huang X; Wu S; Shao D; Deng C; Huang L; Lu Z; Zhou M; Zeng L; Chen D; Wang Y; Chen X; Geng S; Robert W; Tang Z; He C; Li P; Du X J Hematol Oncol; 2018 Feb; 11(1):25. PubMed ID: 29458388 [TBL] [Abstract][Full Text] [Related]
15. Designed improvement to T-cell immunotherapy by multidimensional single cell profiling. Bandey IN; Adolacion JRT; Romain G; Paniagua MM; An X; Saeedi A; Liadi I; You Z; Rajanayake RB; Hwu P; Singh H; Cooper LJ; Varadarajan N J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722906 [TBL] [Abstract][Full Text] [Related]
16. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia. Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S Front Immunol; 2018; 9():239. PubMed ID: 29515572 [TBL] [Abstract][Full Text] [Related]
18. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia. Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532 [TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma. Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597 [TBL] [Abstract][Full Text] [Related]
20. CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease. Lu W; Wei Y; Cao Y; Xiao X; Li Q; Lyu H; Jiang Y; Zhang H; Li X; Jiang Y; Meng J; Yuan T; Zhu H; He X; Jin X; Sun R; Sui T; Liu K; Zhao M Cancer Immunol Immunother; 2021 Dec; 70(12):3501-3511. PubMed ID: 33899130 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]